Vascular Biogenics Ltd. (NASDAQ:VBLT) fell 5.6% on Monday . The stock traded as low as $4.05 and last traded at $4.05, with a volume of 149,384 shares. The stock had previously closed at $4.29.

A number of research firms have weighed in on VBLT. Chardan Capital reaffirmed a “buy” rating on shares of Vascular Biogenics in a report on Tuesday, June 7th. Piper Jaffray Cos. reaffirmed a “buy” rating and set a $14.00 target price on shares of Vascular Biogenics in a report on Tuesday, June 7th. Roth Capital reaffirmed a “buy” rating and set a $22.00 target price on shares of Vascular Biogenics in a report on Thursday, June 9th. Zacks Investment Research upgraded Vascular Biogenics from a “sell” rating to a “hold” rating in a research report on Wednesday, June 15th. Finally, HC Wainwright began coverage on Vascular Biogenics in a research report on Tuesday, June 28th. They set a “buy” rating and a $11.00 price target for the company. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $16.50.

The firm has a 50 day moving average price of $4.14 and a 200-day moving average price of $3.69. The stock’s market capitalization is $91.25 million.

Vascular Biogenics (NASDAQ:VBLT) last posted its earnings results on Thursday, August 11th. The biopharmaceutical company reported ($0.14) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.09. Analysts expect that Vascular Biogenics Ltd. will post ($0.82) earnings per share for the current fiscal year.

Vascular Biogenics Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of first-in-class treatments for cancer. The Company’s program is based on its Vascular Targeting System (VTS) platform technology, which utilizes genetically targeted therapy to destroy newly formed, or angiogenic, blood vessels.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.